Abstract Number: L01 • ACR Convergence 2021
Immunogenicity of mRNA COVID-19 Vaccines at 4 and 12 Weeks Post Full Vaccination in Patients with Inflammatory Rheumatic Diseases
Background/Purpose: Emerging evidence indicates that immunosuppressive therapies may result in reduced immunogenicity –and presumably reduced efficacy- following vaccination with mRNA COVID-19 vaccines but long-term data…Abstract Number: L12 • ACR Convergence 2021
Neither Add-on nor Withdrawal of Methotrexate Impacts Efficacy of IL12/23 Inhibition in Active PsA: Data from a Multicenter Investigator-initiated Randomized Placebo-controlled Clinical Trial on Arthritis, Dactylitis, Enthesitis, Psoriasis, QoL and Function
Background/Purpose: Methotrexate (MTX) is often used as first-line DMARD-therapy in active psoriatic arthritis (PsA). Randomized clinical trials usually require treatment failure or intolerance of csDMARD/MTX…Abstract Number: 0182 • ACR Convergence 2021
Tenderness and Radiographic Progression in Rheumatoid Arthritis and Psoriatic Arthritis
Background/Purpose: In rheumatoid arthritis (RA) and psoriatic arthritis (PsA), swelling is regarded as a sign of synovitis and is associated with radiographic progression. However, recent…Abstract Number: 0569 • ACR Convergence 2021
All-Cause and Cause-Specific Mortality in Spondyloarthritis: A Systematic Review and Meta-Analysis
Background/Purpose: Spondyloarthritides (SpA) represent a group of chronic inflammatory diseases associated with a higher risk of cardio-metabolic comorbidities compared to the general population. It is…Abstract Number: 0990 • ACR Convergence 2021
Lower Incidence of COVID-19 but Higher Mortality in Patients with Inflammatory Arthritis Compared to Controls in Wales, United Kingdom: A Population Epidemiological Study
Background/Purpose: The COVID-19 pandemic has caused over 3 million deaths. Having inflammatory arthritis (IA) and anti-rheumatic medications increase the risk of infections. Comorbidities, common in…Abstract Number: 1323 • ACR Convergence 2021
Uveitis in 406 Patients with Psoriatic Arthritis: Epidemiology, Clinical Characteristics and Relationship with Biological Treatment. Study of a Single University Center
Background/Purpose: Uveitis is the most common ocular manifestation of psoriatic arthritis (PsA). It has been described that uveitis in PsA tends to be insidious, chronic,…Abstract Number: 1341 • ACR Convergence 2021
Ixekizumab Shows a Pattern of Pain Improvement in Patients with and Without Measurable Inflammation in Psoriatic Arthritis
Background/Purpose: The efficacy of ixekizumab (IXE) and adalimumab (ADA) in patients with psoriatic arthritis (PsA) has been previously reported using ACR 50 and Psoriasis Area…Abstract Number: 1357 • ACR Convergence 2021
Clinical and Molecular Profiles Determining Cardiovascular Risk in Psoriatic Arthritis: Specific Response to Apremilast and Methotrexate
Background/Purpose: 1) to evaluate clinical and subclinical markers of cardiovascular (CV) disease risk and its relationship with inflammation, disease activity and metabolic comorbidities in PsA…Abstract Number: 1774 • ACR Convergence 2021
Blood-based Immune Profiling Combined with Machine Learning Discriminates Psoriatic Arthritis from Psoriasis Patients
Background/Purpose: Early detection of psoriatic arthritis (PsA) in psoriasis (Pso) patients is crucial for timely treatment and prevention of structural joint damage. We aimed to…Abstract Number: 1792 • ACR Convergence 2021
Participation in Psoriatic Arthritis (PART2) – a Cross-sectional Study of Work Impairment in Psoriatic Arthritis Patients in the Netherlands
Background/Purpose: Psoriatic arthritis (PsA) can lead to pain, disability and a loss of quality of life [Rosen, Rheumatology 2012]. PsA can also lead to impairments…Abstract Number: 1809 • ACR Convergence 2021
Efficacy of Tofacitinib on Enthesitis in Patients with Active Psoriatic Arthritis
Background/Purpose: Enthesitis (inflammation where the tendon, ligament, or joint capsule insert into the bone) has been associated with higher disease activity and reduced quality of…Abstract Number: 1827 • ACR Convergence 2021
Psoriatic Arthritis, Female Sex and Increased Baseline Skin Severity Are Associated with Drug Persistence in Ustekinumab-Treated Patients with Psoriasis in the BADBIR Cohort
Background/Purpose: Skin and joint symptoms both contribute to the burden of disease in psoriatic arthritis (PsA).1 More severe skin symptoms in patients with both skin…Abstract Number: 0183 • ACR Convergence 2021
Efficacy and Safety of Risankizumab for Active Psoriatic Arthritis: 24-Week Results from the Phase 3, Randomized, Double-blind Clinical Trial for CsDMARD-IR and Bio-IR Patients
Background/Purpose: Risankizumab (RZB) is a humanized immunoglobulin G1 monoclonal antibody that specifically inhibits interleukin 23 by binding to its p19 subunit. RZB is being investigated…Abstract Number: 0571 • ACR Convergence 2021
The National Incidence of Clinically Diagnosed Psoriatic Arthritis in Sweden 2014-2016
Background/Purpose: Psoriatic arthritis (PsA) incidence estimates vary considerably, and nationwide estimates are sparse. In Sweden, PsA is typically diagnosed in specialized care, although a limited…Abstract Number: 1005 • ACR Convergence 2021
CD209/CD14+ Dendritic Cells Characterization in Rheumatoid and Psoriatic Arthritis Patients: Activation, Synovial Infiltration and Therapeutic Targeting
Background/Purpose: Dendritic cells (DCs) are a heterogeneous population of professional antigen-presenting cells which are at the interface between innate and adaptive immunity. A specific subset…
- 1
- 2
- 3
- …
- 49
- Next Page »